Collaborative Drug Discovery Releases Next Generation Database for Both Private Collaborations and Public Open Access

Collaborative Drug Discovery (CDD, Inc) is pleased to announce the introduction of its next generation database technology. Collaborative Drug Discovery’s Web-based database enables scientists to collaborate in novel, global efforts to more effectively develop new drug candidates for commercial and humanitarian markets. The technology enables novel community-based research efforts that become more and more useful as additional participants contribute data. Publicly available data sets currently in the system include the FDA orphan and approved drugs and small molecule drug discovery data dating back over half a century. These data sets pertain to a diverse group of neglected diseases, including malaria, tuberculosis, African Sleeping Sickness, Chagas Disease and Leishmania.

Customers can also securely archive, mine, and collaborate around their small molecule preclinical drug discovery data in invitation-only, username-password protected groups.

The CDD Database is one of the easiest to use drug discovery informatics platforms available today. In designing the product, CDD has focused on making it easy enough for first year graduate students to use, yet powerful enough to satisfy the needs of experienced drug discovery scientists. In the July 2007 release of the Database, CDD has completely overhauled the user interface to make it easier to navigate and comprehend, has simplified the batch uploading of molecule and assay data, and has made the entire application more robust and secure.

Researchers can choose to keep their data private or share any or all of it with other research groups in the community. By default, labs using the CDD database only share their imported data privately with fellow lab members. A subset of the data is available openly to the public at no cost (please contact register@collaborativedrug.com for access).

Using the CDD technology, researchers can:

  • Permanently archive their drug-centric data
  • Mine chemical and biological data for lead optimization
  • Access data instantaneously and securely
  • Connect with multidisciplinary experts, yielding new insights
  • Avoid duplication of research effort
  • Optimize the use of valuable research resources
  • Facilitate current and future collaborations
  • Accelerate target validation and drug discovery
  • Leverage a practical mechanism to maximize the benefit of collaborative data while minimizing intellectual property protection costs

For more information please visit: https://www.collaborativedrug.com/